DocGo Inc. (DCGO) Earnings Call Transcript & Summary
March 15, 2022
Earnings Call Speaker Segments
Steve Halper
executiveThanks, Donna. Ahead of handing things over to management, I want to share a few comments about forward-looking statements. Everything said on this conference call that isn't a historical fact qualifies as a forward-looking statement. Terms such as anticipate, believe, estimate, expect, intend, guidance, confidence, target, project, along with comparable expressions, are typically how we flag those forward-looking statements. Such forward-looking statements don't guarantee future performance, and they could involve, and are subject to, particular risks, uncertainties, and other factors that might impact DocGo's business, financial condition, and other operating results. Those include, without limitation, the risk factors and other qualifications found in DocGo's annual report on Form 10-K, quarterly reports filed on Form 10-Q, and other reports and statements DocGo files with the SEC, to which we direct your attention. Actual outcomes and results could differ materially from what these forward-looking statements express or imply. DocGo expressly disclaims any intent or obligation to update these forward-looking statements. With that, I'm pleased to hand the call over to Stan Vashovsky, Chief Executive Officer and Co-founder of DocGo. Stan?
Stan Vashovsky
executiveAppreciate that, Steve, and thanks to all of you for being on this call — our first one since completing the DocGo and Motion Acquisition Corporation deal, which we told you about in March 2021 and wrapped up on November 5th. I've got a handful of comments about the business, and after that I'll hand things to Andre, who will walk through the financials. Following that, we'll open it up for your questions. By virtually any yardstick, 2021 was an extremely strong year for us. Andre will get into the numbers thoroughly, but I'd like to touch on several highlights; we're happy to share that total company revenue for full year 2021 came in at $318.7 million, which ran well ahead of what we had expected. That works out to growth above 239% compared with the $94 million of revenue we posted for full year 2020. In the same way, we're reporting adjusted full year 2021 EBITDA of $25.1 million, which reflects solid profitability and marks a substantial step up from the adjusted EBITDA loss of $8.1 million we posted for full year 2020; we delivered positive net income for both the full year and the fourth quarter, and each of those is a significant improvement versus the net losses we posted for Q4 2020 and full year 2020; worth noting as well that revenue tied to COVID testing is estimated at roughly $110 million. When we look at 2022, we're being conservative and have built our projections without any COVID testing revenue beyond the close of the second quarter. That said, demand from our customers is strong in both mobile health and transportation services, so we're comfortable issuing full year guidance of $400 million-$420 million for 2022. That implies a 26%-32% increase over 2021, or 65% growth if you strip out non-recurring COVID testing revenue from the second half of each year. Stepping back for anyone who doesn't know our story yet, DocGo is a top provider of last mile healthcare delivery services. What does that mean? We bring high-quality, highly affordable healthcare services to patients right where they are, at the moment they need them the most. Our operations sit in two separate divisions, mobile health and mobile transport. Mobile health, which is the biggest engine behind our growth, delivers in-person healthcare to patients in cases where a trip to a doctor's office or hospital might not be needed. A lot of companies deliver patient care outside traditional settings. What sets our mobile health business apart is DocGo's reliance on highly trained licensed practical nurses and paramedics who practice under physician licenses within our network of medical practices throughout the United States. That lets our clinicians operate under a far broader scope of practice than the way they were used previously. Thanks to this innovative model, DocGo has been able to assemble a large, cost-efficient labor force capable of facilitating a wide range of medical treatments that historically have been delivered by more expensive nurses, physician assistants, nurse practitioners, and medical doctors. With this model, DocGo has been able to grow our clinical staff substantially even while the country faced a shortage of workers, and to deliver many kinds of top-tier medical care and procedures to patients at a far reduced price. When we use that staff to treat people where they live, where they work, and in unconventional locations, we assist in preventing expensive, needless trips to the ER. Bedside procedures, preventive treatment, giving medication, monitoring, plus assorted shots, EKGs, ultrasounds, infusion therapy, and a great deal more all fall under what we offer. We sign agreements straight with government bodies, businesses, and hospital networks, after which we deliver services straight to their members, and payment comes from the contracting organization rather than from the patient. As I noted, we have on staff many licensed practical nurses and paramedics, along with standard nurses, PAs, and MDs, whose main role is training and medical oversight. A point I believe deserves mention: the bulk of our practitioners are our own employees. They aren't contractors; in our view, this produces happier customers and more dedicated staff and, in the end, superior care for those we treat. DocGo's outstanding scores on major online job sites serve as a crucial metric showing how satisfied our employees are. Ratings of their time with our company have been submitted by hundreds of workers, and we hold a 4.2 rating on Glassdoor and a 4.1 on Indeed — results that sit well above those of our rivals; we have delivered mobile health solutions across 29 states and hold licenses to offer such services in still more markets throughout the United States. Because penetration in our sector is currently quite low, a large amount of untapped opportunity remains for us to chase, all while we keep expanding in the markets where we're already established. From 2019 through 2021, our overall revenue, leaving out COVID testing, posted a compound annual growth rate of 182%, hitting $207 million in 2021 versus only $48.3 million in 2019; this remarkable expansion stems from adding revenue tied to several sizable, fresh and broadened mobile health contracts, together with ongoing growth and geographic reach in our transportation operation. A particularly noteworthy contract unveiled in January that will fuel future growth is the one with Aetna covering New York and New Jersey. Through this multi-year deal, we can deliver distinctive on-demand medical services to an entire population exceeding 2.5 million people. Even if only a modest share of those patients switch to our sought-after at-home services, this represents a major opportunity for us. Among the newest offerings we're most enthusiastic about is our direct-to-consumer option. With medical co-pays and deductibles rising steadily, we perceive a chance to bring money-saving treatment choices straight to patients looking for care for non-emergency conditions. We're at an early stage of testing this B2C offering and intend to apply what we learn from the pilot and bring these services into a number of markets during 2022. A distinctive element of the mobile health service we offer is the technology platform we built specifically for this purpose, which connects smoothly with healthcare ecosystems already in place and delivers improved care coordination. It's meant for use by patients along with their families, care providers, and facilities, and among its numerous core functions and benefits, it links up with electronic healthcare records from well-known industry leaders like Epic and Allscripts, so that every piece of patient information sits in one single repository. Beyond generating improved care coordination and a better patient experience, these intricate EMR integrations give DocGo a considerable competitive edge. Our additional offerings in medical transportation — essentially meaning we supply Uber-like on-demand ambulance patient transfer solutions between clinical settings; this isn't 911 emergency work. A fleet of more than 300 ambulances delivers pre-scheduled high acuity medical transportation. Though we have a limited number of wheelchair vans and medical sedans, 99% of transportation revenue is generated by high-margin ambulance transport. For our ambulances, we created a CapEx-light model in which vehicles are leased via GE Capital on five-year terms. Once the lease period concludes, we can send our vehicles back and move up to the newest models. We keep partnerships going with several of the biggest and most highly regarded healthcare providers in the industry, among them Fresenius, Jefferson, and UCHealth, plus Northwell and HCA.
Stan Vashovsky
executiveWe're noticing that long-term agreements spanning multiple years are increasingly moving away from fee-for-service structures and toward a lease hour approach, where we provide the vehicles, equipment, and personnel for a set daily charge. This model gives customers dedicated resources that accelerate patient transfers, along with a rebate component that lowers their costs as they improve scheduling efficiency, while for us it delivers greater revenue predictability and stronger gross margin results. Thanks to strategic partnerships we maintain with Fresenius, Jefferson, and others, our contracts carry over $500 million in potential revenue. Between 2019 and 2021, our medical transport segment's revenue grew at a 35% compound annual rate, reaching $84 million for the entirety of 2021 — about 26% of total revenue. At present, we offer medical transportation in 11 states, and more licenses are awaiting approval. Next, let me cover several operational achievements from the quarter. We disclosed a collaboration with Carnival, the biggest cruise line globally, under which medical teams will be stationed aboard ships to bolster the medical personnel already in place. This builds on the embarkation services we currently offer, and we're bringing those to more ports. We shared news about a collaboration with Visiting Physician Services, aimed at providing non-urgent care within the home for seniors and individuals confined to their homes across New Jersey and the neighboring tri-state region. As the biggest geriatric house call operation in New Jersey, Visiting Physician Services will, thanks to this alliance, reach more patients and respond more quickly. We introduced new offerings, including mobile health services for people living in San Diego, California, plus a mobile Suboxone program targeting those experiencing street homelessness in New York; these represent only a handful of the varied services in our portfolio. Now, regarding market opportunity: the U.S. addressable market for what we provide is substantial and mostly still untapped. Over the last several years, virtual care has expanded quickly, with COVID acting as a major catalyst. That trend helped drive our 2021 results, and beyond that, the ties we built allowed us to demonstrate what DocGo's mobile health services can deliver for a variety of new clients, scaling those ties in numerous instances to bring in more offerings. One estimate puts the potential virtual portion of Medicare, Medicaid, and commercial outpatient office plus home health spending at $250 billion, roughly 20%. Even so, around $80 billion of that virtual care needs certain in-person follow-up, and right now no widely accessible in-home option exists for hands-on clinical services. Also, the medical transport sector is very broken up and expanding at a steady pace, driven by an older population and more people living with chronic illness. When we put together what we see as the potential in mobile health and in transportation, we figure the TAM for what we offer just within the United States comes to roughly $102 billion. In the same vein, McKinsey released a report not long ago that found as much as $265 billion of medical care now provided in healthcare facilities will move into the home by 2025. If you look at Medicare Fee-for-Service plus Medicare Advantage together, that represents a quarter of everything spent. That marks a rise of 3 x to 4 x versus where things stand now, and businesses such as DocGo that can deliver care inside the home are positioned to rank among those gaining the most from this transition. Obviously, we've only just begun to tap what's possible, yet thanks to the investments we've put in, especially when it comes to technology, we think we've built a meaningful competitive edge. With that, I'd like to hand the call to our CFO, Andre Oberholzer, so he can walk us through our financials.
Andre Oberholzer
executiveThanks, Stan. Morning, everyone. Revenue across the whole company came in at a bit more than $121 million for Q4 2021, which works out to 289% growth against the $31 million we posted in Q4 2020. That year-over-year increase came primarily from revenue contributed by a number of new mobile health contracts along with some expanded ones. Mobile health brought in $102.6 million during Q4 2021, versus $15.8 million in Q4 of 2020 — roughly a 6.5x jump. Medical transportation came to $80.7 million, rising 21% from $15.4 million in Q4 of 2020. Worth keeping in mind: if you strip out COVID testing-related revenue from Q4 in both years, Q4 revenue still tripled on a year-over-year basis, which shows solid momentum across our core businesses. Adjusted EBITDA climbed to $17.3 million in Q4 2021, and that's even after making significant investments in regional expansion and infrastructure, compared with an adjusted EBITDA loss of $2.9 million in the same quarter a year earlier. Net income reached $20.3 million in Q4 2021, a major step up from the $4.4 million net loss in Q4 of the previous year. That improvement stems from the big revenue gain in Q4 while certain overhead costs stayed roughly flat versus earlier periods, so a bigger share of the extra revenue flowed down to the bottom line. One more thing I'd like to flag: net income for Q4 2021 includes a $5.2 million gain tied to remeasuring warrant liabilities, and that item has no effect on either cash flow or operations. Now let's look at the full year. Total company revenue for fiscal 2021 was $318.7 million, up 239% from the $94.1 million reported for fiscal 2020, and that's a 4.5% improvement relative to our earlier guidance. Mobile health revenue for fiscal 2021 came to $234.4 million, an increase of 659% from $31 million the year before. Medical transportation revenue was $84.3 million, up 33% from $63.1 million in fiscal 2020. Gross margin for fiscal 2021 landed at 34.4%, which is a 100 basis point gain over the 33.4% recorded in 2020. That margin improvement was mostly driven by a revenue mix shift toward higher margin mobile health revenue. Margins did take a hit from pricier subcontracted or agency labor, from an increase over time as we launched several mobile health projects on an expedited basis, and, to a smaller degree, from higher labor rates. As new markets mature, we anticipate margins improving. Broadly, margins run lower while new projects are launching, since we prioritize getting operations started on time and typically lean on subcontracted labor that costs more. After that initial launch phase passes, we can push margins up toward target levels by scheduling more efficiently with DocGo employees; during 2021, adjusted EBITDA rose to about $25.1 million, or 7.9% of revenue, despite all the investments we've made in regional expansion and corporate infrastructure. In comparison, 2020 saw an adjusted EBITDA loss of $8.1 million. Just as a reminder, adjusted EBITDA is a non-GAAP metric that stands for earnings before interest, taxes, depreciation, and amortization, and it also adds back stock compensation along with the impact from revaluing the warrant liability, plus it adds back non-recurring expenses tied to our public listing. For a reconciliation of adjusted EBITDA to net income, please see our earnings release. During fiscal 2021, net income came in at $19.2 million, a considerable gain compared with the net loss of $14.8 million in 2020. Included in 2021 net income was a $5.2 million gain from revaluing the warrant liability. If you set aside that non-cash, non-operational item, operational net income for the year was $14 million, or 4.4% of revenue. Our cash and cash equivalents stood at $175.5 million as of December 31, 2021. From the public listing, total proceeds to the company were roughly $158 million, net of transaction expenses. Keep in mind that our debt is insignificant, at only about $2 million. Last, to support growth, we brought on more than 900 new employees during Q4 of 2021, which pushed total hires for calendar year 2021 past 2,300, and the total count of medical providers exceeded 3,800 as of year-end. Now let's shift to the 2022 outlook. Stan said earlier that we expect fiscal 2022 revenues of roughly $400 million-$420 million, and we project adjusted EBITDA in a range of $35 million-$41 million. At the midpoint, adjusted EBITDA for 2022 is estimated at 9.4% of revenues, compared with 7.9% in 2021. By segment, we expect the mobile health segment to keep contributing about 70%-75% of revenues, with medical transportation making up the rest; that wraps up my remarks. At this point, we'd like the operator to open the call for questions.
Michael Latimore
analystExcellent. Many thanks, and well done on such a strong year. I suppose I have just a pair of questions. Regarding the medical mobility, or mobile transport, part of the business, could you share some detail on what growth rate you anticipate there, and what might serve as the catalyst for a bit of an uptick in growth for that segment? My second question concerns gross margin. Perhaps offer some guidance regarding where you expect gross margin to land this year.
Stan Vashovsky
executiveYes, Mike, absolutely; when it comes to transportation and that accelerating growth, you know, it depends heavily on how many licenses we're able to obtain across the different states; a few weeks back we put out an announcement. We picked up two additional licenses. Our hope is to enter at least five, and perhaps as many as seven, new markets during 2022; we currently have a number of LOIs out with smaller organizations to purchase their existing licenses. As you're aware, our business model doesn't involve simply entering a market and beginning the search for business. You know, prior to even issuing an LOI, prior to giving any thought to an acquisition, the first thing we typically do is examine how many Fresenius sites exist in that market, and how many of those patients are ones we can truly serve. We put together a thorough pro forma, and after that, if it looks sensible, we commit fully and attempt to make an offer to buy that license out. This provides us with some visibility into the revenue or profits we're able to produce in that market. Another goal of ours is, you know, as soon as we sign and once that license is secured, we want to start generating revenue as fast as we can, typically inside a couple of weeks. To address your question, hopefully we add another five-seven markets during 2022; as far as growth goes, we usually expand our transportation business by roughly 35%, perhaps 40% annually. We've done so consistently across several years. I see no reason that pattern ought to shift at any point soon. If we get lucky, and if we're able to obtain additional licenses, you know, we could certainly aim to speed that up. We face no capital constraints of any kind. You know, we hold ample capital, ample cash on the books, to complete those transactions. In any case, they're typically small. As we've discussed previously, whenever we buy these licenses, there's no cap on how many vehicles we're permitted to deploy. You know, we could put one ambulance on the road or 1,000 ambulances. With an operator's license, no such limit exists; regarding gross margin, you know, we do see some margin erosion during roughly the first 90 days when we undertake a mobile health project. That happens because, quite often, we need to get started very fast. Frequently, the work is located in areas that are far away and where our company might not be established. In those cases, we proceed by partnering with one of the over 30 medical staffing agencies with which we hold contracts. Those agencies supply the temporary workers, while our side supplies the more highly trained medical staff who instruct those temps and prepare them for the initiative we are starting. Under nearly every one of our staffing contracts, we are able to move those workers onto W-2 status once day 60 passes, or once day 90 passes, without paying any fees. Quite often we sacrifice a portion of margin right at the start because we rely on an agency, yet once day 60 arrives, once day 90 arrives, our ultimate aim is to shift those people to W-2 employees and stop having the temp agency supply the workforce. Once day 90 has passed, within mobile health, we aim for roughly 51%-52% gross margin; that figure is what we target going forward on any mobile health project we take on. Occasionally those projects turn out somewhat more profitable, which depends on what kinds of services we deliver under that contract. The gross margin we target in mobile health comes to roughly 52%, 51%-52%, while in transportation it comes to roughly 40%-43%.
Michael Latimore
analystGreat. Thank you.
Stan Vashovsky
executiveSure, Mike.
Steve Braun
analystHey, everyone. Steve Braun here, filling in for Sarah. I had one question regarding the COVID revenue assumption for 2022. I just wanted to check. You mentioned 65% growth, excluding the second-half revenue from 2021 and, I think, 2022. I was hoping to understand how much you're assuming, and then whether you could break that down between 1Q and 2Q.
Stan Vashovsky
executiveRight now, regarding 1Q and 2Q, we look at COVID testing — or rather, we expect COVID testing is going to begin tapering off. It's somewhat difficult for us to provide truly precise figures, since honestly, we haven't gotten many notifications to scale them back as of yet, though we strongly anticipate those notifications will arrive before long. I don't want to provide any details that aren't correct. Our assumption is that by the close of the second quarter, revenue from COVID testing reaches zero. I do think some COVID testing will continue past the second quarter. Bear in mind, Steve, consumer testing isn't something we do. Nearly all of our business is municipal. We serve counties, cities, and states. It's rather improbable that municipalities would eliminate all municipal testing while COVID remains present. We're adopting a highly conservative stance, and in our forecasting as we move ahead with our guidance, we'll simply assume the worst case: COVID testing drops to zero on July 1, and other mobile health services will replace and add that revenue.
Steve Braun
analystOkay. Great. Thank you.
Stan Vashovsky
executiveSure, Steve.
Ryan MacDonald
analystRyan, thanks for the questions, and congratulations on wrapping up a very solid year so impressively. Stan here — first, I'd like to dig into what demand looks like right now, and maybe you can break that down by municipalities versus health systems. On the health system side, with the serious staffing shortages those systems are facing at the moment, are you noticing any demand-driven tailwind, and how does that play into how we should think about the 2022 outlook?
Stan Vashovsky
executiveHey, Ryan. Good to hear from you once more. Sure — demand remains robust. Staffing shortages exist all across the country. In my view, hospitals everywhere, nursing homes, and urgent cares are all understaffed. Every one of them is looking for more nurses. They're looking for physician assistants. For us to pile even more strain onto that would be close to irresponsible. That's exactly why we're pursuing a different model. Our strong belief is that nurses and physician assistants, along with nurse practitioners, devote a large chunk of their day to skills and tests far beneath their training level. So instead of paying top dollar for basic tests and procedures, our strategy is to bring on a licensed practitioner such as an LPN, then up-train that person to deliver those kinds of services. This is far more cost-effective and avoids worsening the existing staffing shortages we see nationwide. As for municipalities, demand there is robust as well. We run what I'd call arguably one of the country's most advanced comprehensive homelessness programs; we hold contracts for those programs in Pennsylvania and New York, and we're now in talks about a pilot in California. We made a presentation to Chicago and a number of other municipalities about that program, and it's drawn a lot of favorable media coverage. Municipal demand is strong. And it isn't limited to homelessness. There are other municipal areas where we supply mobile urgent care units to lower income communities that struggle to obtain quality access to medical services outside of hospitals. Those mobile urgent care units are becoming quite popular. All in all, demand from municipalities and healthcare systems is simply robust. Hospitals are continually seeking to add more services, and giving their patients the chance to come into the hospital or receive treatment for certain things at home is very well received. We do this with a number of hospitals across the country; their customers have responded very positively; every week, we keep presenting the program to new hospital systems eager to learn about the offering. Broadly speaking, perhaps the medical community was a bit skeptical at first about three years ago, when we launched this work. Can you actually up-train LPNs? I believe we've demonstrated through outstanding outcomes that, well, the response is definitely a resounding yes. A great many of these quite simple testing tasks, which historically were handled by more highly trained medical personnel, can be performed by medical staff earning lower wages. When health systems provide that added, let's say, more premium tier of care by allowing patients to choose having a clinician visit them at home, the reception has been incredibly positive. The bottom line is, well, demand is genuinely very strong. Our sales staff are quite occupied, and that's always a positive sign. Beyond merely local municipalities and community hospitals, we are also taking part in major state and federal RFPs, applying that very same idea of licensed practitioners with lesser training who've been upskilled to deliver particular categories of services, clinical services. There are a number of significant RFPs currently out there that we're involved in. I ought to point out that these are solicitations we in earlier times likely would have steered clear of because of working capital demands. We simply lacked the substantial sums of money required to back contracts of that kind. As Andre referenced, we hold ample cash reserves. We intend to deploy that capital. At present we are actively and vigorously pursuing these truly sizable federal, state, and municipal contracts. With some luck, in 2022, we'll secure a few of those major wins.
Ryan MacDonald
analystGreat, that's useful detail, Stan, thank you. For my next question, maybe this one's for Andre — it's good to see such a solid gross margin result, and that lease hour model beginning to work its way into things in the fourth quarter. When we look ahead to fiscal 2022 and consider the assumptions behind the implied gross margin guidance, could you explain how lease hours keep feeding through, and also, given that fuel prices are climbing pretty sharply right now, remind us what effect that could have on the gross margin forecast? Thanks.
Andre Oberholzer
executiveSure. Let me take the fuel piece first, since so many people ask about it. Under the guidance we discussed before, we're assuming a fuel price of roughly $4.30 per gallon for this year. So far this year, the figure is around $3.71, which gives us a bit of cushion relative to what we've guided. If gas prices were to climb by an additional dollar, reaching an average of $5.30, that would add roughly $1.5 million to our fuel costs — equal to somewhere between 39 and 40 basis points of gross margin. So it does matter, though not to the degree it might in other sectors, such as airlines. On gross margin, as Stan said, in a mature market for transportation we move toward the 40% mark, in that high 30%s to 40% band, while mobile health sits at 50% to 51% gross margin. In 2021, as you'll notice, we aren't tracking that way, and one reason — which both Stan and I have pointed out — is that when we roll out all these new projects and the launch window is short because demand exists, we bring in agency staff plus some subcontractors, and that puts pressure on margins. We anticipate a gain of a couple of points in 2022, since we'll have fewer expedited projects spread across a bigger revenue base. We see ourselves moving toward the objective of reaching long-term margins averaging 50%.
Ryan MacDonald
analystThat's useful context. Congratulations once more on a fantastic quarter.
Andre Oberholzer
executiveThanks. Once more, just to be clear, the long-term objective we talked about in earlier guidance is, you know, 3-5 years away, just to clarify.
David Grossman
analystThanks for that. Morning, everyone. Stan, I wanted to ask — I realize a backlog figure isn't something you make public, or anything along those lines, but perhaps you might spend a moment addressing the level of visibility you folks enjoy as you head into the year, drawing on the agreements you currently hold, or maybe some of that repeat business that tends to come in.
Stan Vashovsky
executiveAbsolutely, David. Great to hear your voice once more. When we examine 2022, our guidance, and the added revenue, all of senior management goes through a fairly draining exercise. Essentially, we build it from the ground up, and multiple factors get weighed. Roughly 5 central items get factored in as we arrive at our figure. Honestly, we won't wrap up that exercise until every person agrees that this is a figure we can all stand behind. The 5 items we factor in are, first, extra revenue stemming from current mobile health agreements. Those are agreements already in place, relationships we currently serve, where the other side has approached us about broadening programs that already exist. Second, mobile health agreements already under contract and queued up for rollout; these are signed agreements, funded agreements, yet with a commencement date of 30, 60, or 90 days ahead before revenue starts being captured. Third, mobile health agreements in the queue carrying a likelihood of closing above 75%. We rely on Salesforce, so we work through Salesforce, and contracts at various stages receive a percentage probability of closing. As soon as they reach 75, which typically means we've moved beyond submitting a proposal and have gotten some signal of acceptance, we take those kinds of arrangements and assign them to the pipeline. We examine transportation expansion. We examine markets already won but not yet launched, where pro formas are already finished since we know what awaits us regarding Fresenius and additional customers. We also examine our license pipeline and, with strong confidence, feel at ease that a number of those licenses will close, and we fold those locations into our pro forma. Last, item number 5 is a few modest, immaterial M&A possibilities. Sometimes when you acquire these tiny businesses, there can be some trailing — call it revenue — attached to them. We take those 5 elements, we run through an exhaustive exercise of digging into each one in considerable detail, and afterward we land on a yearly figure that all of us can stand behind. This is something that unfolds gradually — over the course of months — yet ultimately, everyone on the management team supports it, and that is precisely how the figures we presented before for 2022 were arrived at.
David Grossman
analystIn that setting, along with your perspective on COVID, the way the quarters will flow across 2022 is likely quite hard for any of us to forecast. Could you offer any guidance on how we should think about the pattern for both revenue and EBITDA as the year unfolds, since we're in this kind of unusual year?
Stan Vashovsky
executiveYeah. It's definitely what I'd describe as an unusual year, since we do anticipate COVID testing falling off through Q1 and Q2. Ultimately, taking the most conservative view and seeing it reach zero by July 1, with much of that business being replaced by additional mobile health contracts we've either already won or are close to winning. So it's a bit tough for us to really go quarter by quarter, because this is what I'd call a revenue transition year for us. What we can share is that we've been through this five-step process, and I think you're familiar with our track record; across eight quarters, we've never missed guidance, never missed budget. Don't expect and don't hope that we never will going forward; we feel quite confident about the numbers we've shared with you. Some people may think it's too conservative. As a company, we tend to lean toward the conservative side, and if we see the year shaping up better after each quarter, we'll go ahead and raise that guidance after the quarter. But I do agree with you. It is difficult to kind of project out on a quarter-by-quarter basis and give more detail beyond what we've already provided.
David Grossman
analystAll right. Perhaps I could frame the question another way. Given the assumptions you're applying when it comes to COVID, does it make sense to expect revenue to fall sequentially in March and June, and then have that serve as the new baseline from which revenue climbs sequentially during the back half of the year? And look, if there's nothing you can say, that's fine, but I'm just wondering whether that's at least a reasonable assumption for us to make as we consider 2022.
Stan Vashovsky
executiveI'd say it's fair to state that once revenue from COVID testing begins to decline, we hold a solid backlog of agreements that would put that available labor force to work on new projects. In the end, that's what we're aiming for. Our difficulty, you know, lies in getting the timing right; we lock in new agreements; we have a solid sense of what COVID testing revenue looks like and when it will begin to decline, and then we deploy that workforce to pick up and secure new contracts.
David Grossman
analystUnderstood, and thanks. I just wanted to confirm something. Andre, I believe you mentioned $5.2 million — was that a gain? My apologies, I didn't quite catch exactly how that was described for the fourth quarter. Could you say it again?
Andre Oberholzer
executiveYes, of course, happy to. Essentially, it applies to net income along with EBITDA, both for the full year and the quarter. In fact, there is a $5.2 million gain tied to the warrant liability. Back in November, when our merger with Motion became effective, we took on that warrant liability for the warrants still outstanding. On the transaction date, Motion's stock was trading at $10 per share, so the warrants were essentially valued at $10 per share. By the end of December, as we closed out the year and the quarter, the share price had fallen to the $6 range — $6.50 — and that difference, that $3.5, represents a decrease in the warrant liability. It's simply mark to market. We owe the. It's a smaller liability. <<inaudible>> What you'll end up with is — you know, we clearly want to see our price trading above $10. You're going to see it move the opposite direction. That's the reason we highlight it as non-cash and non-operational. It's purely an accounting matter, just like, you know, how stock options, you know, are handled. It's a non-cash item.
David Grossman
analystOK. And when you—since I believe you. OK.
Andre Oberholzer
executivePardon me, please continue.
David Grossman
analystI suppose if we look back at January, you gave early guidance on your quarter, and even so, you came in above it. How does that compare with what you ultimately posted? I believe the figure was roughly $108 million. What accounts for the gap between those two figures? What showed up better than expected, I suppose, that let you beat the guidance you gave in January?
Andre Oberholzer
executiveA number of new projects kicked off around November and December. I won't drown you in accounting jargon, but this is known as a 606 calculation, used to figure out . Depending on the revenue you record, how much will you eventually bring in. With a brand-new project, there's no collection track record for that particular project. We built in certain assumptions that, rather than recognizing 100% of revenue, we recognize a smaller share of revenue, since we needed to forecast that cash collected from that customer would be lower, given our lack of experience. Then, once we moved into January and February and were wrapping up the audit, payments came in on a few of those projects. All at once, that reserve you'd set aside for possible underpayment or nonpayment gets reversed back into income. This is simply the normal audit procedure, examining later receipts against the receivables sitting on your balance sheet; that was the key driver, really, the 606 calculation.
David Grossman
analystUnderstood.
Andre Oberholzer
executiveThat's the usual way things work. There's nothing out of the ordinary here. This isn't an atypical deal. Every quarter's close, and the close of a fiscal year too, follows this same standard procedure.
David Grossman
analystRight. If I may, only one more question. Could you provide some indication of what figure we should apply for the share count during 2022, since 2021 was somewhat atypical, and also the non-GAAP adjustments for 2022 as far as you can see them?
Andre Oberholzer
executiveRegarding share count, at the close of December, we had 100 million shares outstanding. There are 6 million warrants in existence. Roughly 50% are public, and the other 50% remain private warrants. When calculated on a fully diluted basis, that comes to 106 million; we also have roughly 5 million of an earn-out tied to the transaction; if specific price thresholds are reached, then the selling shareholders — so to speak — would receive those 5 million earn-out shares. Right now, you know, I believe the initial earn-out threshold sits at $11.50 per share. You know, that is, you know, the item to forecast for when those 5 million shares will be earned. There are approximately 6 million shares outstanding tied to stock options that have not vested, every one of them. Our standard vesting schedule is four-year vesting. Those are the categories. Roughly 100 million outstanding at present. 6 million warrants, definitely. 5 million possible earn-out down the road, and then approximately 6 million stock options. A portion is vested and a portion is not vested. Does that answer your question?
David Grossman
analystAll right, understood. Yes, that makes sense; so what about those non-GAAP adjustments? Do you have any view on them for 2022?
Andre Oberholzer
executiveLooking ahead, stock compensation is going to remain among the non-GAAP adjustments, since we record that as an expense each quarter without fail. A warrant true-up will also be there for as long as those warrants stay outstanding on the balance sheet; and as I mentioned a moment ago, should the share price climb past $10, well, we'd book a sizable loss, though we'd be glad to see the stock trading higher. Then the remaining adjustment from 2021 had to do with the company's listing. That one won't recur going forward; what you'll see is standard EBITDA plus stock option compensation plus warrant liability all the way through.
David Grossman
analystUnderstood. Excellent. Okay, everyone. Many thanks.
Andre Oberholzer
executiveThanks, David.
David Grossman
analystNo problem at all.
Richard Close
analystSure, and thanks for taking my question. Nice work on a solid year. I only wanted to confirm something — how much revenue came from COVID during 2021? Was the figure you mentioned $110 million?
Andre Oberholzer
executiveYes, that's right.
Stan Vashovsky
executiveRichard-
Andre Oberholzer
executiveSorry, go ahead.
Stan Vashovsky
executivePlease continue, Andre.
Andre Oberholzer
executiveI was about to mention that we figure COVID testing brought in roughly $110 million. The basis for calling it an estimate is that folks sometimes wonder, "How come you don't have the exact figure?" As Stan noted before, consumer testing isn't something we truly handle. Practically 100% consists of agreements with municipalities or states. Payment comes per shift, covering an entire shift's worth of labor. The shift itself takes care of our margins. It makes no difference whether we run a single test or 10 tests during that shift — in certain instances, nothing additional comes our way. In other instances, there's a small amount more. Our contracts began with testing, after which we started layering in vaccines — multiple vaccine types, you know — plus a few other services. Under our labor contracts, testing gets mixed together with other revenue. We needed to review contracts one by one, and our estimate came to roughly $110 million for 2021.
Richard Close
analystAll right.
Stan Vashovsky
executiveRichard, a solid frame of reference here is that our agreements are generally built around a flat daily fee. Say we're delivering a pre-op service at the patient's home — an EKG, blood work, vital signs, and a COVID test — the payment comes per day. There might be small additional charges for certain items, $5 or $10 add-ons. So in that kind of situation, how would you isolate the COVID test alone? That's somewhat difficult. It gets easier when the contract covers nothing but COVID. With some of our work, COVID is just one service among many included under a daily rate. That does make it a bit tricky, but Andre and the team, in my view, did well in arriving at an approximate number.
Richard Close
analystAll right. And to make sure I understand the guidance properly — since you provided guidance, and then described what growth looks like when that item is taken out of the back half, given that for 2022 you anticipate zero revenue from COVID testing during the back half. I simply want clarity on what assumption applies to COVID in the front half. Did you happen to specify a dollar figure in the millions that you anticipate, or not?
Stan Vashovsky
executiveWe have not done that. The explanation is that, first, we would rather not put out a set of figures, a collection of figures, regarding which we cannot be, in essence, completely sure. Even though COVID testing across municipalities has seen volumes decline, and the number of personnel under some agreements has been reduced, honestly, we cannot predict the moment a municipality calls and requests that we cut staffing, because the need has disappeared or shrunk considerably. Essentially, what we are indicating is that the opening six months of this year will follow a path comparable to the opening six months of the prior year. It phases out, moving more toward the second quarter, and finally reaches zero at the start of the third quarter. It would not be, shall we say, professional on our part to simply guess how states and municipalities will carry out reductions across the first and second quarters; internally, we essentially plan it out with a steady decline toward zero as of July 1.
Richard Close
analystAll right. Let me touch on Fresenius briefly. From the filings, I recall you'd shared before how much revenue comes from that client — or partner, rather. What do you anticipate for 2022, or more specifically, what revenue figure tied to Fresenius in 2021? And your view on growing that relationship in 2022.
Stan Vashovsky
executiveWell, once more, we don't give out figures that are specific to a client, to a customer. What I can tell you, though, is that with Fresenius, revenue for 2021 came in at roughly twice what it was in 2020. Assuming we can lock in our licenses across new markets, our hope is that we keep roughly doubling that revenue figure with them, each year. That's genuinely what I'd like to see. I don't believe that's much of a stretch to expect. The partnership with Fresenius remains strong. They operate in all 50 states and run 2,400 clinics. Every one of those has some volume of patients who use private ambulance service, and those patients are ones we serve and are paid quite well for. That business appeals to us since it's recurring, it's steady, and we're able to forecast it with a very high degree of accuracy. Beyond the transportation services, we're also exploring other, let's call them mobile health opportunities, that we could bring to Fresenius and some of their patients. Those conversations are ongoing. There's talk about pilots, until matters get a bit more concrete on their side, in terms of expanding into other opportunities beyond transport. We really won't get into that level of detail until a contract is signed, and then we'd be thrilled to share that with everyone.
Richard Close
analystAll right, just one point of clarification, if I may. My understanding is that Andre mentioned mobility should account for 25%-30% of revenue in 2022. Is that right?
Stan Vashovsky
executiveYes, that is right.
Richard Close
analystAll right. Stan, did I hear you right that you're expecting five to seven additional markets for transportation during 2022?
Stan Vashovsky
executiveMy apologies, Richard. Would you mind saying that again?
Richard Close
analystRegarding transportation, was that five to seven additional markets you mentioned?
Stan Vashovsky
executiveThat's right.
Richard Close
analystAnd that was during 2022?
Stan Vashovsky
executiveCorrect. There are a pair of new market licenses we've already obtained, and we began a soft launch on those earlier in the year. Right now, we likely have nearly 6 LOIs in circulation. I believe it's quite realistic to expect us to enter 5-7 additional transportation markets before the year wraps up.
Richard Close
analystDo the two licenses you obtained correspond to that deal you completed over in Maryland and Pennsylvania, and so forth?
Stan Vashovsky
executiveThat's right. Yep.
Richard Close
analystAll right, regarding EMR integration, you brought that up. Are there any plans to get Cerner — or Oracle, as it's now called — integrated, or is that not important?
Stan Vashovsky
executiveYes. What I'd say is we're integrated with a number of sizable EMRs, especially Epic and Allscripts. In the past, we did some work involving Cerner. What actually pushes this forward is simply what our customers require and ask for. With Epic, that connection runs quite deep. I'd estimate that most of our biggest clients use Epic. Northwell, an Allscripts customer, has solid integration with us on that platform. We've handled some fundamental integration with Cerner; going considerably deeper is certainly possible, though that's driven by what the customer wants and how far they'd like us to take the integration with them. One point I should probably highlight: pulling off these integrations isn't simple. If we reached out on our own to someone at Epic, we'd likely never get beyond the front desk. The sole factor behind our success with these integrations — and why we're likely among a handful, maybe the only firm that has pulled them off — is that our long-term agreements with the hospitals let those hospitals contact the EMR vendor directly and demand the integration. It's Jefferson placing the call to Epic; it's UCHealth. It's Northwell. Once the request originates from them, since they're such a large customer, Epic responds and helps push it through. Allscripts responds and helps push it through. What makes these deep integrations possible is really those long-term, high-quality ties we hold with our hospital systems. This isn't limited to Epic or Cerner. There are roughly 20 other EMRs, the smaller ones, where we've likewise completed some degree of integration. It certainly makes the IP we own stronger.
Richard Close
analystAll right. About Aetna — you brought that up, and it's a fresh channel for you folks, I suppose, or a new group of customers on the payer side. My guess is that there are certain marketing plus onboarding expenses tied to, you know, generating revenue in that segment, which differ from what you see in your typical mobile health operation.
Stan Vashovsky
executiveCould you discuss that a bit, and how we ought to think about— Stan Vashovsky: Yeah
Richard Close
analystIn terms of profitability or go-to-market strategy, how do you accelerate revenue growth there?
Stan Vashovsky
executiveThat's an excellent question, Richard. The truth is, one thing I'm really looking forward to in 2022 is our move into the direct-to-consumer space. Given high co-pays and high deductibles, we observe that consumers are ready to spend a modest sum for concierge-style services delivered at home. We kicked off this service through a partnership based in Canada. The pilot is performing extremely well; at this point we're preparing to bring that offering to the United States. The Aetna deal is the first, shall we say significant, agreement we've entered into that represents a D2C-style product. We don't possess much information that we're able to disclose at this point regarding that initiative. Aaron Severs at our company is in charge of that whole effort. Aaron is a demonstrated leader with plenty of accomplishments to his name, and he's the one guiding our entire B2C offering. Early trials involving, let's say, chosen clients whom we serve on a one-off basis have delivered genuinely positive responses and extremely elevated satisfaction rates. Essentially what you're witnessing is the basis for a forthcoming direct-to-consumer product. A great deal of learning will take place. A great deal of development will go into that initiative. We're accessing — assuming things go well, we're going to access an enormous TAM that our company will gain from for many years ahead; we can't reveal much publicly at this stage aside from the fact that we are fully committed to the direct-to-consumer offering. Aetna is among the first we've signed as we prepare for that. We're holding continuous discussions with a number of other major national payers to provide that service alongside. Once we obtain additional results from our Canada initiative, we will certainly pass those along to you. When we're set to roll out that service formally across the United States past the pilot stage, we will certainly let everybody know.
Stan Vashovsky
executiveYes. Appreciate it. That brings this morning's call to a close. Hopefully you found it useful. Hopefully we managed to get across how excited we are about this year and what comes after. Big opportunities lie ahead of us, and I'm eager for a year that's both very successful and exciting. With that, we're wrapping up, and I truly want to thank all of you for being here. Have a wonderful day, everybody.
Operator
operatorThanks, everyone, for taking part and for your interest in DocGo. At this point you're welcome to drop off the lines or sign out of the webcast, and we hope the remainder of your day goes well.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DocGo Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to DocGo Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DocGo Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.